Home Newsfeeds Oppenheimer Downgrades PLx Pharma to Perform

Oppenheimer Downgrades PLx Pharma to Perform

Oppenheimer analyst Leland Gershell downgrades PLx Pharma (NASDAQ:PLXP) from Outperform to Perform.

byBenzinga Newsdesk

August 15, 2022

1 minute read

Oppenheimer analyst Leland Gershell downgrades PLx Pharma (NASDAQ:PLXP) from Outperform to Perform.

Bitcoin’s Current Cycle Is Outperforming According To These 3 Metrics, Says Analyst

By Khyathi Dalal

June 5, 5:55 AM

Crypto analyst Benjamin Cowen, in his latest podcast, pointed out three important metrics to compare Bitcoin’s (CRYPTO: BTC) return on investment (ROI) across

BTC

Suze Orman Keeps Buying Amazon, Microsoft And… Palantir? ‘Over The Long Run, You Will Win’

By Adam Eckert

October 26, 9:00 AM

Personal finance whiz Suze Orman doesn't think bonds are the best way to build wealth over the long term. Instead, she recommends buying growth stocks — just pick the right ones.

AMZN

News

Titan International’s Chairman Comments Further On Its Current Business And Market Outlook

By Benzinga Newsdesk

October 6, 8:37 AM

CHICAGO, Oct. 6, 2022 /PRNewswire/ -- Titan International, Inc. (NYSE:TWI) ("Titan" or "TWI") today released the following comments from its Chairman of the Board, Morry

TWI

Why This Hedge Fund Manager Plans To Short Apple Stock Ahead Of iPhone 15 Launch Next Week

By Shanthi Rexaline

September 7, 3:17 AM

Apple is facing the twin risk of facing competition from Huawei's newly-launched phone and China ban on iPhones in government offices.

AAPL

Oppenheimer Downgrades PLx Pharma to Perform

Related Posts

Bitcoin’s Current Cycle Is Outperforming According To These 3 Metrics, Says Analyst

Suze Orman Keeps Buying Amazon, Microsoft And… Palantir? ‘Over The Long Run, You Will Win’

Titan International’s Chairman Comments Further On Its Current Business And Market Outlook

Why This Hedge Fund Manager Plans To Short Apple Stock Ahead Of iPhone 15 Launch Next Week